Innovative Research Award
Lingkai Zhang is a researcher affiliated with Fudan University in Shanghai, China, whose scholarly activity is associated with oncology and particularly with research into urothelial carcinoma, tumor biology, immune-cell infiltration, molecular biomarkers, and the tumor immune microenvironment. [1]
Abstract
This academic recognition profile summarizes the research record of Lingkai Zhang of Fudan University within the subject area of oncology. His published work includes investigations of urothelial carcinoma with emphasis on the tumor immune microenvironment, immune-cell infiltration, clinically relevant molecular alterations, proliferative tumor characteristics, and factors associated with patient prognosis or therapeutic response. [1]
Keywords
Oncology, urothelial carcinoma, tumor immunology, tumor immune microenvironment, natural killer cells, CD8+ T cells, ARID1A, molecular biomarkers, cancer prognosis, immunotherapy, tumor proliferation, precision oncology, immune infiltration, cancer biology, translational research. [2]
Introduction
Modern oncology increasingly integrates tumor genomics, immunology, pathology, and clinical outcome data to understand biological heterogeneity and identify variables that may influence disease progression or treatment response. Urothelial carcinoma represents an important setting for such investigations because tumor behavior may be shaped by molecular alterations together with interactions between malignant cells and immune populations in the surrounding microenvironment.[2]
Research Profile
Lingkai Zhang is affiliated with Fudan University in Shanghai, China. Published articles identify an affiliation with the National Health Commission Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University. His ORCID record is identified by 0009-0001-0405-057X, providing a persistent digital identifier for scholarly attribution. [3]
Research Contributions
A principal theme within Zhang’s documented research is the investigation of immune and molecular heterogeneity in urothelial carcinoma. One study examined natural killer cell infiltration and its relationship with sex-dependent clinical outcomes, addressing how immune-cell abundance may have distinct clinical associations across patient groups.[3]
Publications
Lingkai Zhang is a researcher affiliated with Fudan University, China, whose work focuses on oncology, particularly urothelial carcinoma and tumor immunology. His research examines the relationships between immune-cell infiltration, molecular alterations, tumor biology, prognosis, and therapeutic response.His publications include studies on natural killer cell infiltration, ARID1A loss and CD8+ T-cell infiltration, proliferative ecotypes, and TERT promoter alterations in urothelial carcinoma.[4]
Research Impact
The supplied Scopus information reports 8 indexed documents, 9 citations, and an h-index of 2 for Lingkai Zhang. These values describe the research record within the Scopus indexing environment at the time the metrics were supplied. Citation totals and h-index values are dynamic indicators and can change as publications accumulate citations and bibliographic databases update their records. [4]
Award Suitability
For consideration within an Innovative Research Award framework in oncology, Zhang’s research record contains several elements relevant to an innovation-focused academic assessment. These include investigation of the tumor immune microenvironment, integration of molecular alterations with immune-cell characteristics, evaluation of clinically relevant patient cohorts, and exploration of biological classifications associated with prognosis or therapeutic benefit. [5]
Conclusion
Lingkai Zhang’s academic profile at Fudan University is associated with oncology research focused substantially on urothelial carcinoma and its molecular and immunological heterogeneity. His published studies include investigations of natural killer cell infiltration, CD8+ T-cell activity, ARID1A-related tumor characteristics, TERT-associated disease features, and proliferation-based tumor ecotypes. [5]
External Links
References
- Elsevier. (n.d.). Scopus author details: Lingkai Zhang, Author ID 59507405200. Scopus.
https://www.scopus.com/authid/detail.uri?authorId=59507405200
- ORCID. (n.d.). ORCID record: Lingkai Zhang, 0009-0001-0405-057X. ORCID.
https://orcid.org/0009-0001-0405-057X
- Medical Lab Scientist Awards. (n.d.). Academic and scientific recognition platform.
https://medicallabscientist.com/
- Liu, Z., Zhang, L., Jin, K., et al. (2025). ARID1A Loss plus CD8+ T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma. Clinical Cancer Research, 31(20), 4311–4322.
https://doi.org/10.1158/1078-0432.CCR-25-0816
- Zhang, L., Liu, Z., Ding, Y., Sun, J., Wu, Y., Su, X., Jin, K., et al. (2025). Natural killer cell infiltration elicits gender-dependent dichotomous clinical outcomes in urothelial carcinoma. Cancer, 131(24), e70196.
https://doi.org/10.1002/cncr.70196